人工子宮設施市場－全球產業規模、佔有率、趨勢、機會、預測：按技術、應用、最終用戶、地區和競爭格局分類，2021-2031年

全球人工子宮設施市場預計將從 2025 年的 3.2311 億美元大幅成長至 2031 年的 6.4877 億美元，複合年成長率為 12.32%。

這一新興領域專注於開發用於體外受精（IVF）的生物技術環境。這些設施利用合成羊水和先進的氧氣供應系統，精心模擬母體子宮環境，旨在支持極低出生體重嬰兒的正常生長和器官成熟。推動該市場成長的主要因素是全球迫切需要提高IVF嬰兒的存活率並減輕其相關的嚴重長期健康併發症，這使其區別於自動化和人工智慧等更廣泛的技術趨勢。然而，社會接受度和關於胎兒存活能力的法律定義對商業化構成了重大障礙。根據美國早產兒基金會（March of Dimes）的數據，2024年美國的IVF率仍高達10.4%，令人擔憂，凸顯了對這些醫療干預措施的迫切需求。這項持續高企的統計數據強調了為IVF機構提供先進新生兒護理解決方案的迫切需求。阻礙市場擴張的一個主要挑戰是缺乏完善的倫理和法律體制來監管IVF和人體臨床試驗。這一監管空白對市場准入和廣泛應用構成了重大障礙。

市場促進因素

全球早產率的不斷攀升是人工子宮市場的主要驅動力，其根本原因在於迫切需要降低早產兒極高的死亡率。傳統的新生兒重症監護往往無法為妊娠28週前出生的胎兒提供必要的生理保護，而仿生妊娠環境正作為解決這一重大挑戰的方案而備受關注。為了凸顯問題的嚴重性，跨機構兒童死亡率估計小組（UNFMO）在2024年3月發布的報告指出，預計2023年將有230萬新生兒在出生後28天內死亡，其中早產仍是主要死因。如此巨大的生命損失凸顯了該市場的核心提案：將懷孕延長至適當的階段。此外，即使在醫療體系發達的國家，這場危機依然存在。美國疾病管制與預防中心（CDC）在2024年11月指出，報告期間美國約14.0%的嬰兒死亡是由早產和低出生體重造成的，凸顯了對這類設施的需求。對周產期研究和開發的投入不斷增加，正在加速人工子宮技術從動物實驗模型轉化為人體臨床應用的發展。創業投資公司和生物技術機構認知到體外支持器官成熟的系統的商業性潛力，並正在該領域投入大量資金。 Vitara Biomedical公司在2024年11月宣布獲得5,000萬美元的B輪資金籌措，用於推進其系統進入首次人體臨床試驗，這就是該領域資金籌措強勁的一個顯著指標。這筆巨額專款的注入對於克服建構這些複雜生物技術環境的高昂營運成本至關重要。此類投資支撐著市場的成長軌跡，並使該行業更接近將體外受精（體外發育）標準化為一種醫療干預手段，用於管理高風險懷孕和減輕與早產相關的長期併發症。

市場挑戰

全球人工子宮市場擴張的最大障礙在於缺乏完善的體外受精和人體臨床試驗倫理及法律體制，而圍繞胎兒存活能力的社會接受度和法律定義等問題更使情況雪上加霜。這種缺乏全面的法律和倫理基礎設施是限制市場發展的主要瓶頸，阻礙了市場從動物試驗向實際商業醫療解決方案的有效過渡。由於缺乏明確的人體臨床試驗監管路徑，生物技術公司無法充分檢驗人工羊水環境對人類胎兒的安全性和有效性。這種法律真空為投資者和保險公司造成了不穩定的環境，他們不願為那些在懷孕期間胎兒「人格」的法律地位不明的情況下運作的機構提供資金。因此，該技術仍停留在研發階段，無法在新生兒加護病房（NICU）得到緊急應用。儘管該技術潛力巨大，但臨床進展有限，這充分體現了監管停滯的嚴重性。根據納菲爾德生物倫理委員會2024年的報告，體外發育領域仍然受到嚴格的生物倫理法規的限制，包括國際上強制執行的人類胚胎研究14天期限。這反映出立法機構普遍不願擴大宮外發育的許可範圍。這種監管僵化直接阻礙了人工子宮設施獲得必要的營運許可證，從而嚴重限制了市場利用對先進早產兒護理的巨大需求的能力。

市場趨勢

研究型醫院中專用子宮外生命支持單元的快速發展表明，市場正從實驗室環境向專用醫療基礎設施發生重大轉變。醫療機構正日益投資建設配備複雜流體系統、氧氣供應迴路和無菌環境的專用設施，這些設施對於體外開發系統的人體臨床試驗至關重要。這一趨勢是基礎設施建設的關鍵一步，確保醫院在獲得監管部門批准後能夠立即實施人工子宮技術。為了支持這項發展，《貝克爾醫院評論》在2024年10月報道稱，費城兒童醫院已將其7.5億美元債券中的4.8億美元用於建造一座新的研究大樓，該大樓將容納先進的胎兒研究項目並支持EXTEND系統的臨床應用。同時，面向臨床應用的策略性官民合作關係的出現，正成為為臨床前檢驗和原型改進相關的高昂成本提供資金的關鍵機制。由於創業投資資金籌措波動較大，生物技術聯盟擴大透過與慈善基金會和金融機構合作來獲得非稀釋性資金籌措。這些夥伴關係對於彌合動物實驗與人體應用之間的差距至關重要，確保了專注於器官成熟和生理穩定性的長期研究計畫的持續發展。這一趨勢的一個典型例證是，正如新聞稿中所宣布的，Fundacion La Caixa 於 2024 年 2 月向 BCNatal 研究聯盟追加撥款 430 萬歐元，用於推進其人工胎盤原型機的二期研發和臨床實用化。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球人工子宮設施市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依技術（生物反應器、子宮外支撐裝置等）
  • 依目的（產前護理、新生兒護理）
  • 依最終使用者（專科醫院、研究中心、體外受精（IVF）中心）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美人工子宮設施市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲人工子宮設施市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區人工子宮設施市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲人工子宮設施市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲人工子宮設施市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球人工子宮設施市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• American University of Beirut（AUB）
• Biotex Inc.
• California Preterm Birth Initiative
• Emmaus Life Sciences, Inc.
• Hebrew University
• Institute of Life Sciences
• Juno Perinatal Healthcare
• Sera Prognostics, Inc.
• Shanghai First Maternity and Infant Hospital
• SomaGenics Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Artificial Womb Facility Market is projected to expand significantly, growing from USD 323.11 Million in 2025 to USD 648.77 Million by 2031, demonstrating a Compound Annual Growth Rate (CAGR) of 12.32%. This emerging sector focuses on developing biotechnological environments designed to gestate premature fetuses outside the human body. These facilities utilize synthetic amniotic fluid and advanced oxygenation systems to meticulously replicate the maternal uterine environment, aiming to support normal growth and organ maturation for extremely premature infants. The primary impetus for this market's growth is the urgent global need to enhance survival rates and mitigate severe long-term health complications linked to preterm births, a factor distinct from broader technological trends like automation or AI. Public acceptance and legal definitions of fetal viability, however, represent substantial obstacles to commercialization. Highlighting the critical demand for such medical interventions, the preterm birth rate in the United States remained at a concerning 10.4% in 2024, according to the March of Dimes. This persistent statistic underscores the vital need for advanced neonatal care solutions that artificial womb facilities are designed to provide. A significant challenge impeding market expansion is the profound absence of established ethical and regulatory frameworks governing ectogenesis and human trials. This regulatory void creates considerable hurdles for market entry and widespread adoption.

Market Driver

The escalating global prevalence of preterm births serves as the primary catalyst for the artificial womb facility market, driven by the critical need to reduce mortality rates among extremely premature infants. Traditional neonatal intensive care often struggles to provide the necessary physiological protection for fetuses born before 28 weeks, creating a significant void that bio-mimetic gestation environments aim to address. Highlighting the gravity of this issue, the United Nations Inter-agency Group for Child Mortality Estimation reported in March 2024 that an estimated 2.3 million newborns died within their first 28 days of life in 2023, with prematurity remaining a leading cause. This substantial loss of life validates the market's core value proposition: extending gestation to viable terms. Furthermore, the crisis persists even in advanced healthcare systems; the Centers for Disease Control and Prevention noted in November 2024 that preterm birth and low birth weight accounted for approximately 14.0% of all infant deaths in the United States during the reported period, reinforcing the demand for these facilities. Increasing investments in perinatal research and development are accelerating the transition of artificial womb technologies from experimental animal models toward human clinical viability. Venture capital firms and biotechnology organizations are channeling significant capital into this sector, recognizing the commercial potential of systems capable of supporting extracorporeal organ maturation. A notable indicator of this financial momentum was Vitara Biomedical's announcement in November 2024 that it secured $50 million in Series B financing to advance its system toward first-in-human clinical trials. This substantial influx of dedicated funding is crucial for overcoming the high operational costs associated with establishing these complex bio-technological environments. Such investment validates the market's trajectory, moving the industry closer to standardizing ectogenesis as a medical intervention for managing high-risk pregnancies and mitigating the long-term disabilities associated with premature birth.

Market Challenge

The most significant challenge impeding the expansion of the Global Artificial Womb Facility Market stems from the lack of established ethical and regulatory frameworks governing ectogenesis and human trials, compounded by issues surrounding public acceptance and the legal definitions of fetal viability. This absence of a comprehensive legal and ethical infrastructure stands as the primary bottleneck, preventing this market from transitioning effectively from experimental animal studies to viable commercial healthcare solutions. Without clear regulatory pathways for human clinical trials, biotechnology companies cannot adequately validate the safety or efficacy of synthetic amniotic fluid environments for human fetuses. This legislative void creates a precarious environment for investors and insurers, who are hesitant to fund facilities operating under an undefined legal status concerning the 'personhood' of a gestating fetus, thus stalling the technology in the research and development phase and preventing its deployment in neonatal intensive care units where it is urgently needed. The severity of this regulatory stagnation is evident in the limited clinical progress, despite the technology's considerable potential. According to the Nuffield Council on Bioethics in 2024, the field of ectogenesis remains constrained by rigid bioethical statutes, such as the internationally observed 14-day limit on human embryo research. This signals a broader legislative reluctance to expand permissions for extra-uterine development. Such regulatory immobility directly prevents artificial womb facilities from obtaining the necessary licensure to operate, thereby severely hampering the market's ability to capitalize on the substantial demand for advanced premature infant care.

Market Trends

The establishment of specialized extra-uterine life support units in research hospitals is rapidly advancing, signaling a significant shift in the market from experimental laboratory settings to dedicated healthcare infrastructure. Medical institutions are increasingly investing in purpose-built facilities capable of housing the intricate fluidics, oxygenation circuits, and sterile environments essential for human clinical trials of ectogenesis systems. This trend represents a critical move towards infrastructural readiness, ensuring that hospitals will possess the capacity to deploy artificial womb technology immediately upon regulatory clearance. Validating this expansion, Becker's Hospital Review reported in October 2024 that the Children's Hospital of Philadelphia allocated $480 million from a $750 million bond specifically for a new research tower, which will accommodate advanced fetal research programs and support the translation of the EXTEND system. Concurrently, the rise of strategic public-private partnerships for clinical translation is emerging as a vital mechanism to sustain the high costs associated with pre-clinical validation and prototype refinement. As venture capital funding can fluctuate, biotechnology consortia are increasingly securing non-dilutive funding through alliances with philanthropic foundations and banking institutions. These partnerships are crucial for bridging the gap between animal studies and human application, ensuring the continuity of long-term research projects focused on organ maturation and physiological stability. An exemplary instance of this trend is the Fundacion La Caixa's award of an additional €4.3 million to the BCNatal research consortium in February 2024, as noted in their press release, to advance their artificial placenta prototype towards a second phase of development and clinical viability.

Key Market Players

• American University of Beirut (AUB)
• Biotex Inc.
• California Preterm Birth Initiative
• Emmaus Life Sciences, Inc.
• Hebrew University
• Institute of Life Sciences
• Juno Perinatal Healthcare
• Sera Prognostics, Inc.
• Shanghai First Maternity and Infant Hospital
• SomaGenics Inc.

Report Scope

In this report, the Global Artificial Womb Facility Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Artificial Womb Facility Market, By Technology

• Bioreactors
• Extrauterin Support Devices
• Others

Artificial Womb Facility Market, By Application

• Prenatal Care
• Neonatal Care

Artificial Womb Facility Market, By End user

• Super Specialty Hospitals
• Research Centers
• In-Vitro Fertilization Centers (IVF)

Artificial Womb Facility Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Artificial Womb Facility Market.

Available Customizations:

Global Artificial Womb Facility Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Artificial Womb Facility Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (Bioreactors, Extrauterin Support Devices, Others)
  • 5.2.2. By Application (Prenatal Care, Neonatal Care)
  • 5.2.3. By End user (Super Specialty Hospitals, Research Centers, In-Vitro Fertilization Centers (IVF))
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Artificial Womb Facility Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Application
  • 6.2.3. By End user
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Artificial Womb Facility Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End user
  • 6.3.2. Canada Artificial Womb Facility Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End user
  • 6.3.3. Mexico Artificial Womb Facility Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End user

7. Europe Artificial Womb Facility Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Application
  • 7.2.3. By End user
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Artificial Womb Facility Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End user
  • 7.3.2. France Artificial Womb Facility Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End user
  • 7.3.3. United Kingdom Artificial Womb Facility Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End user
  • 7.3.4. Italy Artificial Womb Facility Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End user
  • 7.3.5. Spain Artificial Womb Facility Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End user

8. Asia Pacific Artificial Womb Facility Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Application
  • 8.2.3. By End user
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Artificial Womb Facility Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End user
  • 8.3.2. India Artificial Womb Facility Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End user
  • 8.3.3. Japan Artificial Womb Facility Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End user
  • 8.3.4. South Korea Artificial Womb Facility Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End user
  • 8.3.5. Australia Artificial Womb Facility Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End user

9. Middle East & Africa Artificial Womb Facility Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Application
  • 9.2.3. By End user
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Artificial Womb Facility Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End user
  • 9.3.2. UAE Artificial Womb Facility Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End user
  • 9.3.3. South Africa Artificial Womb Facility Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End user

10. South America Artificial Womb Facility Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Application
  • 10.2.3. By End user
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Artificial Womb Facility Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End user
  • 10.3.2. Colombia Artificial Womb Facility Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End user
  • 10.3.3. Argentina Artificial Womb Facility Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End user

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Artificial Womb Facility Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. American University of Beirut (AUB)
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Biotex Inc.
• 15.3. California Preterm Birth Initiative
• 15.4. Emmaus Life Sciences, Inc.
• 15.5. Hebrew University
• 15.6. Institute of Life Sciences
• 15.7. Juno Perinatal Healthcare
• 15.8. Sera Prognostics, Inc.
• 15.9. Shanghai First Maternity and Infant Hospital
• 15.10. SomaGenics Inc.

16. Strategic Recommendations

17. About Us & Disclaimer